Table 1.
Clinicopathological status of 23 patients whose blood (33 samples/visits) was used for TACCs isolation and characterization by nanomechanical and immunocytochemical profiling. The CS/CR and metastasis status at the time of visit/blood draw is presented. The “update” refers to information obtained at least 6 months after the visit (in the case of patient No. 1: after the start of ADT).
| Sample Number (visit) | Disease spread (update) | PSA at draw (ng/ml) | Treatments: primary, secondary, tertiary, quat. | Stage at diagnosis, prostatectomy | Gleason: diagnosis, prostatectomy | Months from prostatectomy | BCR | Months from ADT | CS/CR (update) |
|---|---|---|---|---|---|---|---|---|---|
| 1* | Regional | 0.24 | surgery, ADT | cT2b, Nx, Mx pT3a, N1, Mx, R1 |
4+5, 5+4 | 35 | yes | −5 | CS (CS) |
| 2* | Regional | 0.18 | surgery, ADT | cT2b, Nx, Mx pT3a, N1, M0, R0 |
4+3, 4+4 | 25 | yes | 3 | CS (CS) |
| 3* (1) | ND | 0.04 | surgery, radiation | cT1c, N0, M0 pT3b, N0, MX |
3+4, 4+3 | 10 | no | none | CS (CS) |
| 4 (2) | ND | 0.10 | same | same | same | 17 | no | none | CS (CS) |
| 5* | ND | 0.14 | surgery | T1c, Nx, Mx pT2c, pNx, Mx |
3+3, 3+3 | 140 | no | none | CS (CS) |
| 6* | ND | 14.99 | ADT | T2b, N0, M0 NA |
4+4, NA | none | no | 0 | CS (CS) |
| 7* (1) | M1b | 704.3 | ADT, chemo, ADT, radiation | cT4, N1, M1 NA |
4+5, NA | none | no | 0 | CS (CR) |
| 8 (2) | M1b | NA | same | same | same | none | no | 6 | CS (CR) |
| 9* | ND (M1b) |
37.17 | ADT, radiation | cT3 | 4+3, NA | none | no | 0 | CS (CS) |
| 10* | M1a and M1b | 4.2 | ADT, surgery, radiation | NA | 4+4, 4+5 | 44 | D | 0 | CS (CS) |
| 11* | Regional | 2.94 | surgery, ADT | cT2b, N0, M0 pT3b, N1, MX |
4+5, 4+5 | 35 | yes | 0 | CS (CS) |
| 12* | ND | 1.36 | surgery, ADT, radiation | NA, pT3a/b, R1, N0, Mx | 4+3, 4+3 | 18 | yes | 0 | CS (CS) |
| 13 (1) | ND | 0.51 | surgery, radiation, ADT | cT2c, N0, M0 pT3b, N0, Mx |
4+5, 3+4 | 32 | yes | 0 | CS (CR) |
| 14 (2) | ND | NA | same | same | same | 38 | yes | 6 | CR |
| 15 | Regional | 0.06 | surgery, ADT | cT1c, N0, M0 pT3b, N1, M0, R1 |
3+4, 4+4 | 7 | no | 0 | CS (CS) |
| 16 | Regional | 1.83 | surgery, radiat., ADT, chemo | NA, pT2b,N1 |
4+5, 4+5 | 29 | D | 25 | CS (CS) |
| 17 | M1a and M1b | 102 | chemo, ADT, radiation | NA | NA | none | no | >24 | CR |
| 18 (1) | M1b | 12.39 | ADT, XRT, chemo | cT3,N1,M1 NA |
4+5, NA | 25 | yes | 28 | CS (CS) |
| 19 (2) | M1b | NA | same | same | same | 28 | yes | 31 | CS (CS) |
| 20 | ND | 0.24 | surgery, radiation, ADT | cT2a, N0, M0 pT3b, NX, MX |
3+4, 4+4 | 45 | yes | none | CS (CS) |
| 21 (1) | M1a | 4.68 | ADT, radiation | NA | 3+4, NA | 45 | no | 45 | CS (CS) |
| 22 (2) | M1a | NA | same | same | same | 54 | no | 54 | CS (CS) |
| 23 (1) | ND | 7.22 | radiation, ADT | NA | 3+4, NA | 27 | yes | 0 | CS (CS) |
| 24 (2) | ND | NA | same | same | same | 37 | yes | 10 | CS (CS) |
| 25 (1) | ND | 0.96 | radiation, ADT | pT3a, N1, M0 | 4+5, NA | 120 | yes | 0 | CS (CS) |
| 26 (2) | ND | NA | same | same | same | 124 | yes | 4 | CS (CS) |
| 27 (1) | ND | 18.3 | radiation, ADT | T1c, Nx, Mx | 3+3, NA | 72 | no | 0 | CS (CS) |
| 28 (2) | ND | NA | same | same | same | 75 | no | 3 | CS (CS) |
| 29 (1) | M1a | 0.05 | surgery, ADT | NA, pT3b, N1, M0, R1 |
3+4, 4+4 | 1 | D | 0 | CS (CS) |
| 30 (2) | M1a | NA | same | same | same | 4 | D | 3 | CS (CS) |
| 31 (1) | M1a | 43.8 | ADT, radiation | cT1c, N1, M0 | 4+5, NA | 0 | no | 0 | CS (CS) |
| 32 (2) | M1a | M1a | same | same | same | 4 | no | 7 | CS (CS) |
| 33 | ND | 9.66 | radiation, ADT | cT2b,Nx, Mx | 3+4, NA | 156 | yes | 0 | CS (CS) |
(1), (2) with consecutive numbers – blood samples obtained during 1st and 2nd visits of the same patient (10 patients)
- CTCs used for comparison with urine prostate cells (Table S1); ADT – androgen deprivation therapy; chemo – chemotherapy; prostatectomy: surgery and/or radiation therapy; BCR – biochemical recurrence; CS/CR – castration sensitive/resistant; D – PSA always detectable; quat. – quaternary treatment; NA – no data available; ND – not detected.